Diagnosis and genetic analysis of polycythemia in children and a novel EPAS1 gene mutation

Basit Öğe Kaydı
dc.authoridKOCAAGA, AYCA/0000-0003-0434-8445
dc.contributor.authorÇakmak, Hatice Mine
dc.contributor.authorKartal, Ömer
dc.contributor.authorKocaağa, Ayça
dc.contributor.authorBildirici, Yasar
dc.date.accessioned2023-07-26T11:54:12Z
dc.date.available2023-07-26T11:54:12Z
dc.date.issued2022
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground: Unlike in adults, there is no consensus on management and diagnosis of polycy-themia in children. This study aims to evaluate the diagnosis and verify the algorithm in chil-dren with polycythemia. Methods: Seventy-nine children with polycythemia were followed-up in our pediatric hematology-oncology clinic between December 15, 2019, and July 15, 2021. After eliminating secondary causes (hypoxia, pulmonary, cardiac diseases), we checked for genetic mutations, including congenital erythrocytosis gene panel (JAK, EPOR, EPAS1, EGNL1, HBB, HBA, BPGM, and VHL). We also compared parameters for secondary and idiopathic polycythemia groups. Results: Of the 79 children, thirty-five had secondary polycythemia (hypoxia, pulmonary, car-diac diseases), and one was diagnosed with a novel likely pathogenic mutation c.2089C > G; p.Pro697Ala in exon 13 of EPAS1 gene. Others (n = 35) had persistent and idiopathic polycy-themia. Here, we compared the idiopathic and secondary cases. We found that the ratio of family history of polycythemia (n = 4 (9.5%) vs 0%, respectively) was higher in the second group (p = 0.009). In addition, the mean age (14.7 +/- 3.52 vs 13.4 +/- 4.67 respectively) (p = 0.042) and the ratio of erythroid hyperplasia in bone marrow [n = 3 (8.6%) vs 0% respec-tively] (p = 0.003) was higher in the idiopathic polycythemia group, compared to secondary polycythemia patients. Conclusion: Finding the genetic defect in polycythemia is a significant issue. Due to being a rarity in children, the first line JAK mutation analysis should be performed in selected cases. This study is the first description of a Turkish patient with EPAS1 p.Pro697Ala mutation, thereby expanding our knowledge about the clinical features of the disease. However, new investigations are required to confirm its function. Copyright 2022, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/ by-nc-nd/4.0/).en_US
dc.identifier.doi10.1016/j.pedneo.2022.06.006
dc.identifier.endpage617en_US
dc.identifier.issn1875-9572
dc.identifier.issn2212-1692
dc.identifier.issue6en_US
dc.identifier.pmid36002380en_US
dc.identifier.scopus2-s2.0-85136587990en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage613en_US
dc.identifier.urihttps://doi.org/10.1016/j.pedneo.2022.06.006
dc.identifier.urihttps://hdl.handle.net/20.500.12684/12761
dc.identifier.volume63en_US
dc.identifier.wosWOS:000893177100009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorÇakmak, Hatice Mine
dc.language.isoenen_US
dc.publisherElsevier Taiwanen_US
dc.relation.ispartofPediatrics and Neonatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz$2023V1Guncelleme$en_US
dc.subjectA Novel Epas1 Mutation; Children; Idiopathic; Polycythemiaen_US
dc.subjectErythrocytosisen_US
dc.titleDiagnosis and genetic analysis of polycythemia in children and a novel EPAS1 gene mutationen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
12761.pdf
Boyut:
621.1 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu